Catalogue Number: AB02058-10.160-BT-ABA
| Manufacturer: | Vector Laboratories, Inc (ABA) |
| Type: | Recombinant Monoclonal |
| Shipping Condition: | Blue Ice |
| Unit(s): | 500 ug |
| Host name: | Human |
| Clone: | SR4 |
| Isotype: | IgG1 |
| Immunogen: | The original antibody was selected after one round of ribosome display using three high diversity libraries (concave, loop and covex) followed by three rounds of phage display and panning against biotinylated RBD as a bait and increasing the stringency of selection with every round. The last round of selection was against 5nM RBD. |
| Application: | ELISA, FACS, FC, NT, BLI |
S
Purified
Recombinant Monoclonal
43740568
P0DTC2
SARS CoV 2 S glycoprotein; COVID-19 Spike protein; RBD; Receptor Binding Domain; E2 glycoprotein; E2; Human coronavirus 2 spike glycoprotein; Peplomer protein; S glycoprotein; SARS coronavirus 2 S protein; SARS coronavirus 2 Spike Protein; SARS CoV 2 Spike protein; SARS CoV 2; SARS-CoV-2 S protein; SARSCoV2; SARS-COV-2 S protein; SARS-COV-2 Spike glycoprotein; SARSCOV2 Spike protein; Severe acute respiratory syndrome 2 spike glycoprotein; Severe acute respiratory syndrome virus 2 spike glycoprotein; Spike glycoprotein; 2019-nCoV
Store at 4⁰C for up to 3 months. Note, this antibody is provided without added preservatives, it is therefore recommed this antibody be handled under sterile conditions. For longer storage, aliquot and store at -20⁰C.
Structural alignment of the SR4-RBD complex and ACE2-RBD complex revealed that binding of SR4 did not cause any noticable conformation changes of the RBD. ELISA was used to screen the libraries to identify specific RBD binders. Neutralization activity of the sybody was checked by pre-incubating pseudoviral particles with different concentrations of sybody before infection of VeroE6-hACE2 cells. The rate of infection was then measured by fluorescence-activated cell sorting (FACS). IC50 value of SR4 was determined to be 5.90 µg m/L. The binding kinetics between sybodies and the RBD was assessed using bio-layer interferometry (Li et al., 2020).
This chimeric human antibody was made using the variable domain sequences of the original VHH format, for improved compatibility with existing reagents, assays and techniques.